VAXX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States...

Stats
Šios dienos apimtis	5.08M
Vidutinė apimtis	906 257
Rinkos kapitalizacija	14.66M
EPS	$0 ( 2024-03-25 )
Kita pelno data	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-01	Ray Sumita	Buy	425 000	Employee Stock option (right to buy)
2023-11-03	Paula Molina Rene	Buy	0
2023-10-02	Powchik Peter	Buy	159 744	Stock option (right to buy)
2023-10-01	Ray Sumita	Buy	0
2023-09-06	Prime Movers Lab Fund I Lp	Sell	5 308	Class A Common Stock

INSIDER POWER
55.09
Last 91 transactions
Buy: 6 350 518 \| Sell: 2 608 586

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.52 (weak)

Signal:(77.889) Neutral

Vaxxinity, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MEUSW	0.894
VYGR	0.876
ADXN	0.863
LIAN	0.855
IMAB	0.852
WWD	0.85
HSDT	0.849
ICUI	0.848
PXLW	0.845
PRAX	0.84

10 Labiausiai neigiamai susiję koreliacijos
MTSL	-0.822
EA	-0.815

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vaxxinity, Inc. Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

-0.01
( neutral )

Vaxxinity, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2023
Pajamos:	$0
Bruto pelnas:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.68M (0.00 %)
EPS:	$-0.600

FY	2021
Pajamos:	$66 000.00
Bruto pelnas:	$-1.87M (-2 834.85 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.